MacuMira and Keeler Announce Global Partnership to Expand Dry AMD Therapy

MacuMira and Keeler Announce Global Partnership to Expand Dry AMD Therapy

Partnership includes launch in Australia and New Zealand, distributed exclusively by ParagonCare, with additional markets to follow.

Windsor, UK and Calgary, Canada – Keeler Ltd, a global leader in ophthalmic innovation with more than a century of heritage, and MacuMira Medical Devices Inc, a pioneering Canadian company, today announced a global strategic partnership. Under the agreement, Keeler will manufacture the MacuMira device and lead its exclusive distribution in Australia and New Zealand through leading diversified healthcare distributor, ParagonCare, together we are officially launching at the annual RANZCO meeting (Royal Australian and New Zealand College of Ophthalmology). MacuMira will continue to offer the therapy directly in Canada, where it has been available since early 2024. The companies also plan to support distribution in additional markets as MacuMira expands internationally.

Dry age-related macular degeneration (Dry AMD) is the leading cause of vision loss among adults worldwide, with few effective treatment options. MacuMira is a unique medical device that uses precisely delivered microcurrent to stimulate retinal pigment epithelium (RPE) cells, enhancing mitochondrial activity to support cellular energy production and preserve or improve visual function in people living with Dry AMD. MacuMira’s non-invasive retinal microcurrent stimulation device represents a breakthrough approach, designed to restore visual function and independence for patients through a 32-minute, in-clinic therapy.

“Keeler has a proud tradition of advancing eye care with uncompromising quality, craftsmanship and innovation in eyecare,” said Andy Harbidge, Keeler Managing Director. “This partnership marks a transformative moment as we align Keeler’s heritage and reach with MacuMira’s groundbreaking therapy. Together, we will bring new hope to patients and clinicians worldwide.”

MacuMira’s therapy is already established in Canada, where thousands of treatments have been delivered safely since early 2024. Clinical evidence, including a randomized controlled trial published in the International Journal of Retina and Vitreous, has demonstrated meaningful improvements in visual acuity and contrast sensitivity.

“This collaboration with Keeler accelerates our mission to change the trajectory of Dry AMD,” said Justin Sather, CEO MacuMira. “By combining Keeler’s global presence with our novel science, we are redefining how this disease is managed, restoring not only vision but also dignity and independence to patients.”

“We are delighted ParagonCare can support this partnership by exclusively distributing the innovative MacuMira device across Australia and New Zealand” said Carmen Riley, CEO, ParagonCare. “Our aim is to enable eye care professionals with innovative solutions to achieve optimal patient care against progressive vision loss.”